Ceftazidime-Avibactam as a Salvage Treatment for Severely Infected Immunosuppressed Children.
Humans
Ceftazidime
/ administration & dosage
Child
Male
Female
Anti-Bacterial Agents
/ pharmacology
Azabicyclo Compounds
/ administration & dosage
Drug Combinations
Child, Preschool
Salvage Therapy
Immunocompromised Host
Adolescent
Gram-Negative Bacterial Infections
/ drug therapy
Drug Resistance, Multiple, Bacterial
/ drug effects
Retrospective Studies
Infant
Microbial Sensitivity Tests
adverse events
gram-negative bacteria
hematological disease
hematopoietic stem cell transplantation
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2024
2024
Historique:
received:
08
03
2024
accepted:
20
07
2024
medline:
5
8
2024
pubmed:
5
8
2024
entrez:
5
8
2024
Statut:
epublish
Résumé
Multidrug-resistant Gram-negative bacteria (MDR-GNB) are becoming increasingly common around the world, with carbapenems frequently serving as a last resort but being threatened by the growing incidence of carbapenemase-producing bacteria. Ceftazidime-avibactam (CAZ/AVI) is a potential agent against MDR-GNB but with limited clinical experience, particularly in critically ill immunosuppressed children. This study analyzed the use of CAZ/AVI as salvage treatment in severely infected immunosuppressed children from September 2019 to July 2022. Patients with confirmed GNB infection who received CAZ/AVI were matched with patients who received other antibiotics. Twenty-five critically ill immunosuppressed children treated with CAZ/AVI were included. The majority had hematologic diseases. All patients presented with sepsis in all 30 courses. Septic shock presented in 36.7% of these courses. The primary sites of infection included bloodstream infection (20.0%), skin and skin structure infection (20.0%), intra-abdominal infection (13.3%) and hospital-acquired pneumonia (10.0%). Twelve of the 25 (48.0%) patients had positive microbiological cultures, mainly CAZ/AVI could be considered a salvage strategy for immunosuppressed children with confirmed GNB infection. Caution should be taken when CAZ/AVI is applied to these patients in the absence of GNB recovery.
Sections du résumé
Background
UNASSIGNED
Multidrug-resistant Gram-negative bacteria (MDR-GNB) are becoming increasingly common around the world, with carbapenems frequently serving as a last resort but being threatened by the growing incidence of carbapenemase-producing bacteria. Ceftazidime-avibactam (CAZ/AVI) is a potential agent against MDR-GNB but with limited clinical experience, particularly in critically ill immunosuppressed children.
Methods
UNASSIGNED
This study analyzed the use of CAZ/AVI as salvage treatment in severely infected immunosuppressed children from September 2019 to July 2022. Patients with confirmed GNB infection who received CAZ/AVI were matched with patients who received other antibiotics.
Results
UNASSIGNED
Twenty-five critically ill immunosuppressed children treated with CAZ/AVI were included. The majority had hematologic diseases. All patients presented with sepsis in all 30 courses. Septic shock presented in 36.7% of these courses. The primary sites of infection included bloodstream infection (20.0%), skin and skin structure infection (20.0%), intra-abdominal infection (13.3%) and hospital-acquired pneumonia (10.0%). Twelve of the 25 (48.0%) patients had positive microbiological cultures, mainly
Conclusion
UNASSIGNED
CAZ/AVI could be considered a salvage strategy for immunosuppressed children with confirmed GNB infection. Caution should be taken when CAZ/AVI is applied to these patients in the absence of GNB recovery.
Identifiants
pubmed: 39100219
doi: 10.2147/DDDT.S467967
pii: 467967
pmc: PMC11297580
doi:
Substances chimiques
avibactam, ceftazidime drug combination
0
Ceftazidime
9M416Z9QNR
Anti-Bacterial Agents
0
Azabicyclo Compounds
0
Drug Combinations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3399-3413Informations de copyright
© 2024 Zhu et al.
Déclaration de conflit d'intérêts
All authors declared no conflicts of interest in this work.